Inovio Pharmaceuticals Inc (NASDAQ:INO)

1.96
Delayed Data
As of Jun 27
 +0.01 / +0.52%
Today’s Change
1.38
Today|||52-Week Range
9.96
-60.72%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$440.9M

Company Description

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Contact Information

Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Plymouth Meeting Pennsylvania 19462-1111
P:(267) 440-4200
Investor Relations:
(484) 362-0076

Employees

Shareholders

Mutual fund holders26.18%
Individual stakeholders2.05%
Other institutional14.54%

Top Executives

Jacqueline E. SheaPresident, Chief Executive Officer & Director
Peter D. KiesChief Financial Officer
Kate E. BroderickSenior Vice President-Research & Development
Stephen KemmerrerSenior Vice President-Engineering Development
Laurent M. HumeauChief Scientific Officer